{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:38:31Z","timestamp":1767908311967,"version":"3.49.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Basal cell cancer is the most common cutaneous malignancy. It rarely presents with locally advanced or metastatic disease. Rare presentations such as intraorbital invasion remain a difficult clinical problem with significant potential morbidity. There is no review of sonic hedgehog pathway inhibitors (HPIs) for intraorbital basal cell cancer, and evidence regarding optimal management is limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate the evidence for the management of intraorbital basal cell cancer with HPIs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>A search to identify evidence for treatment intraorbital basal cell cancers with HPIs to date was performed in PubMed database and OVID using the phrases \u201cbasal cell cancer\/carcinoma\/BCC,\u201d \u201cintraorbital,\u201d \u201corbital,\u201d \u201cocular,\u201d \u201cperiocular,\u201d \u201cvismodegib,\u201d \u201cGDC-0449,\u201d \u201csonidegib,\u201d and \u201cLDE224,\u201d in various combinations with Boolean operators \u201cAND\u201d and \u201cOR.\u201d<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Rigorous clinical trials have previously reported the use of vismodegib and sonidegib in locally advanced and metastatic basal cell carcinoma (BCC). However, specific descriptions of treatment of intraorbital tumors are rarely presented in detail adequate for analysis. Twenty-two cases of intraorbital BCC treated with vismodegib have been described in the literature, and no cases using sonidegib were identified. These vary in quality, but highlight important questions regarding optimal treatment duration, follow-up, and adjunctive therapies. Reports describing locally advanced BCC in various facial and periocular locations, but without specific mention of intraorbital invasion, were excluded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Vismodegib is an attractive eye and vision-sparing option in patients with locally advanced intraorbital basal cell cancer whose other options often include exenteration, radiation, or other radical surgery.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000001640","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T19:26:56Z","timestamp":1536262016000},"page":"17-25","source":"Crossref","is-referenced-by-count":10,"title":["Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Jason","family":"Mathis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Doerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherrif F.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the University of Rochester Medical Center, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archdermatol.2010.4","article-title":"Prevalence of a history of skin cancer in 2007: results of an incidence-based model","volume":"146","author":"Stern","year":"2010","journal-title":"Arch Dermatol"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13671-014-0069-y","article-title":"Advanced basal cell carcinoma: epidemiology and therapeutic innovations","volume":"3","author":"Mohan","year":"2014","journal-title":"Curr Dermatol Rep"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma","volume":"353","author":"Rubin","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/bjc.2014.270","article-title":"Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective","volume":"111","author":"Lear","year":"2014","journal-title":"Br J Cancer"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.1097\/GOX.0000000000001424","article-title":"Vismodegib for locally advanced periocular and orbital basal cell carcinoma: a review of 15 consecutive cases","volume":"5","author":"Wong","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for periocular and orbital basal cell carcinoma","volume":"131","author":"Gill","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"3S Suppl 1","key":"R9-20230814","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1097\/IOP.0000000000000565","article-title":"Secondary resistance to vismodegib after initial successful treatment of extensive recurrent periocular basal cell carcinoma with orbital invasion","volume":"33","author":"Papastefanou","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1080\/0284186X.2016.1206212","article-title":"Vismodegib and surgery combined\u2014effective treatment of locally advanced basal cell carcinoma","volume":"55","author":"Paulsen","year":"2016","journal-title":"Acta Oncol"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0002-9394(14)71523-5","article-title":"Clinical characteristics associated with orbital invasion of cutaneous basal cell and squamous cell tumors of the eyelid","volume":"113","author":"Howard","year":"1992","journal-title":"Am J Ophthalmol"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00002341-200211000-00008","article-title":"Management of periocular basal cell carcinoma with modified en face frozen section controlled excision","volume":"18","author":"Wong","year":"2002","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ophtha.2004.11.036","article-title":"Orbital invasion by periocular basal cell carcinoma","volume":"112","author":"Leibovitch","year":"2005","journal-title":"Ophthalmology"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/IOP.0b013e31816d954d","article-title":"Basal cell carcinoma of the eyelids and periorbital region in a Turkish population","volume":"24","author":"Soysal","year":"2008","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jdcr.2016.06.010","article-title":"Spontaneous resolution of advanced basal cell carcinoma after short-pulse treatment with hedgehog pathway inhibitor","volume":"2","author":"Jacobsen","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","article-title":"Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area","volume":"31","author":"Demirci","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaophthalmol.2013.4430","article-title":"Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma","volume":"131","author":"Kahana","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","article-title":"Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome","volume":"160","author":"Ozgur","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","article-title":"An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma","volume":"71","author":"Ally","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaad.2016.02.1235","article-title":"Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC)","volume":"75","author":"Kwon","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"537","DOI":"10.6004\/jnccn.2017.0051","article-title":"Implementation of systemic hedgehog inhibitors in daily practice as neoadjuvant therapy","volume":"15","author":"Tang","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R22-20230814","first-page":"219","article-title":"Vismodegib as a neoadjuvant treatment to mohs surgery for aggressive basal cell carcinoma","volume":"14","author":"Alcalay","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/bjo.2004.062471","article-title":"Orbital exenteration: a 13 year manchester experience","volume":"89","author":"Rahman","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/bjophthalmol-2017-310681","article-title":"Multicentred international review of orbital exenteration and reconstruction in oculoplastic and orbit practice","volume":"102","author":"Zhang","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.joms.2015.09.019","article-title":"Orbital exenteration to manage infiltrative sinonasal, orbital adnexal, and cutaneous malignancies provides acceptable survival outcomes: an institutional review, literature review, and meta-analysis","volume":"74","author":"Hoffman","year":"2016","journal-title":"J Oral Maxillofac Surg"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.ophtha.2010.02.013","article-title":"Globe-sparing surgery for medial canthal basal cell carcinoma with anterior orbital invasion","volume":"117","author":"Madge","year":"2010","journal-title":"Ophthalmology"},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bjo.2005.072892","article-title":"Mortality following exenteration for malignant tumours of the orbit","volume":"89","author":"Rahman","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.bjps.2007.02.012","article-title":"Orbital exenteration for advanced periorbital skin cancers: 20 years experience","volume":"60","author":"Nassab","year":"2007","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0360-3016(99)00057-7","article-title":"Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity","volume":"44","author":"Takeda","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N Engl J Med"},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13023-016-0506-z","article-title":"Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials","volume":"11","author":"Chang","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/jamadermatol.2016.0780","article-title":"Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies","volume":"152","author":"Jacobsen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","volume":"16","author":"Basset-Seguin","year":"2015","journal-title":"Lancet Oncol"},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/archdermatol.2012.2354","article-title":"Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma","volume":"148","author":"Chang","year":"2012","journal-title":"Arch Dermatol"},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jamadermatol.2016.5058","article-title":"A novel alternate dosing of vismodegib for treatment of patients with advanced basal cell carcinomas","volume":"153","author":"Becker","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC Cancer"},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.anplas.2015.01.002","article-title":"Locally advanced basal-cell carcinoma: combined alternative treatments beyond surgery","volume":"60","author":"Amici","year":"2015","journal-title":"Ann Chir Plast Esthet"},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1001\/jamadermatol.2015.4592","article-title":"Effective and tolerable treatment of advanced basal cell carcinoma with vismodegib despite renal insufficiency","volume":"152","author":"Maul","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamadermatol.2015.0326","article-title":"Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma","volume":"151","author":"Pollom","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/DSS.0000000000000731","article-title":"Histologic findings of tumor lysis in advanced basal cell carcinoma treated with vismodegib","volume":"42","author":"Powell","year":"2016","journal-title":"Dermatol Surg"},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jaad.2015.12.035","article-title":"Four-year experience with vismodegib hedgehog inhibitor therapy","volume":"74","author":"Simone","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archdermatol.2007.28","article-title":"Systematic reviews: grading recommendations and evidence quality","volume":"144","author":"Robinson","year":"2008","journal-title":"Arch Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201901000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T19:48:15Z","timestamp":1692042495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201901000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001640","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}